{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.35296","value":"89.6908"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.69578","value":"-7.1908"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"C1D4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.46117","value":"-8.2532"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"C1D11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.03911","value":"-5.8696"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"C1D18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.00664","value":"2.3052"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"C2D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.50060","value":"-6.3632"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"C2D4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.44543","value":"-9.3021"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"C2D11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.75881","value":"-4.7388"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"C2D18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.80991","value":"-2.9103"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.90582","value":"-6.7050"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"C3D4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.03351","value":"-3.3451"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"C4D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.52264","value":"-5.3312"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"C5D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.77817","value":"-26.5000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"C6D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.82505","value":"-2.4789"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"End of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"eGFR creatinine was evaluated using CKD-EPI formula. Absolute change from baseline in eGFR was presented.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle. The first three cycles are given in combination with Cisplatin at dose of 40 milligrams per square meter (mg/m2) once daily on Cycle 1 Day 2 (C1D2, C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2) With 70 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 35 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of Xevinapant at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"OG000","title":"Sequence 1"}],"paramType":"MEAN","populationDescription":"SAS included all participants who were administered any dose of any study intervention. Here \"number analyzed\" signifies participants who were evaluable at specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, C1D4, C1D11, C1D18, C2D1, C2D4, C2D11, C2D18, C3D1, C3D4, C4D1, C5D1, C6D1 and End of treatment (Day 134) (each cycle is of 3 weeks)","title":"Absolute Change From Baseline in eGFR","type":"SECONDARY","unitOfMeasure":"mL/min/1.73 m^2"}